The House Energy & Commerce Committee on Wednesday (July 15) passed five bipartisan FDA policy bills that would increase the agency’s authority over imported counterfeit medical devices, stop gaming of certain orphan drug exclusivity provisions, boost use of continuous manufacturing, empower FDA to require labeling updates for generic drugs, and allow the agency to add food ingredients to the list of major allergens. All bills cleared the committee by voice vote. Among a slate of 30 bipartisan bills the full...